SEC Form 4 · accession 0001144204-16-107341

KIORA PHARMACEUTICALS INC · KPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Morton Goldberg

Director

Period of report

Jun 3, 2016

Accepted (ET)

Jun 7, 2016 · 5:42 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001372514

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 3, 2016	M	33,775	$0.6478	A	43,216	D
Common Stock^F1	Jun 3, 2016	S	4,650	$3.3743	D	38,566	D
Common Stock^F2	Jun 6, 2016	S	5,543	$3.2546	D	33,023	D
Common Stock^F3	Jun 7, 2016	S	746	$3.3144	D	32,277	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F4	$0.6478	Jun 3, 2016	M	14,493	D	—	Sep 29, 2018	Common Stock	14,493	D
Stock Option (right to buy)^F4	$0.6478	Jun 3, 2016	M	5,353	D	—	Jan 29, 2020	Common Stock	5,353	D
Stock Option (right to buy)^F4	$0.6478	Jun 3, 2016	M	2,276	D	—	Jan 29, 2020	Common Stock	2,276	D
Stock Option (right to buy)^F4	$0.6478	Jun 3, 2016	M	3,809	D	—	Jun 25, 2020	Common Stock	3,809	D
Stock Option (right to buy)^F4	$0.6478	Jun 3, 2016	M	5,112	D	—	Jan 14, 2021	Common Stock	5,112	D
Stock Option (right to buy)^F5	$0.6478	Jun 3, 2016	M	2,732	D	—	Dec 23, 2022	Common Stock	2,732	D

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4The Reporting Person was granted options to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. Each option become exercisable immediately upon grant.
F5The Reporting Person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on December 23, 2013, with 2.79% of the shares underlying the option vesting monthly thereafter.